and development of
new antibiotics and
WHO is recommending that farmers and the food industry stop using antibiotics routinely to promote growth and prevent disease in healthy animals.
The new WHO recommendations aim to help preserve the effectiveness of antibiotics that are important for human medicine by reducing their unnecessary use in animals. In some countries, approximately 80% of total consumption of medically important antibiotics is in the animal sector, largely for growth promotion in healthy animals.Read more
Prof. Marc Bonten, chairman of the focus area Infection & Immunity at UMC Utrecht, and board member of NADP, wrote a blog on the use of bacteriophages to treat infections caused by resistant bacteria.Read more
As part of implementation of the Global Action Plan on Antimicrobial Resistance, WHO drew up a list of priority antibiotic-resistant pathogens (priority pathogens list; PPL) to guide research into and the discovery and development of new antibiotics. Furthermore, the pipeline of antibacterial products that are in clinical development was analyzed.Read more
In a recent press release Summit Therapeutics announced they received the BARDA Contract worth $62 mil. for the development of a new treatment against Clostridium difficile infections.Read more
A joint action on antimicrobial resistance and healthcare-associated infections (EU-JAMRAI), bringing together member states, international organizations, institutes and universities to tackle the AMR threat was launched on 13 September, at the French Ministry of Health in Paris.Read more
No Posts Found.